AZD 5658
Alternative Names: AZD-5658Latest Information Update: 03 Apr 2025
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Conduit Pharmaceuticals
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders
- Preclinical Systemic lupus erythematosus
- Discontinued Obesity; Type 2 diabetes mellitus